Form 4 for IA INNOVATIVE SOLUTIONS & SUPPORT INC
Accepted 2025-04-02 00:00:00 ET · period of report 2025-02-18 · accession 0001104659-25-031314 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-02 | 2025-02-18 | IA | DiGiovanni Jeffrey | CFO | A - Grant | $0.00 | +17.5K | 84.6K | +26% | $0 |
| D | 2025-04-02 | 2025-02-18 | IA | DiGiovanni Jeffrey | CFO | A - Grant | $0.00 | +33.3K | 33.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Restricted Stock Units | 2025-02-18 | A | A | 17,462 | $0.00 | 84,618 | D | — | — | (F1) The RSUs were granted pursuant to the Company's 2019 Stock-Based Incentive Compensation Plan. The number of RSUs is based on the methodology determined by the Company's compensation committee prior to the date of grant on February 18, 2025. The grant was confirmed by the Company's board of directors on April 1, 2025. Each RSU represents the right to receive one share of Common Stock, subject to adjustment as provided in the Award Agreement. The RSUs are scheduled to vest in accordance with the following schedule: 1/4th on the first anniversary of the grant date and 1/12th on each quarterly anniversary of the grant date thereafter, subject to continued employment by the reporting person. |
| 2 | Derivative | Non-Qualified Stock Option (Right to Buy) | 2025-02-18 | A | A | 33,259 | $0.00 | 33,259 | D | $9.88 · — to 2035-02-18 | 33,259 Common Stock | (F2) The non-qualified stock option was granted pursuant to the Company's 2019 Stock-Based Incentive Compensation Plan. The number of shares of Common Stock underlying the option is based on the methodology determined by the Company's compensation committee prior to the date of grant on February 18, 2025. The grant was confirmed by the Company's board of directors on April 1, 2025. The option is scheduled to vest in accordance with the following schedule: 1/4th on the first anniversary of the grant date and 1/12th on each quarterly anniversary of the grant date thereafter, subject to continued employment by the reporting person. The option becomes exercisable, if at all, if the price of the Company's common stock on the Nasdaq Stock Market is equal to or greater than $9.8785 for 20 consecutive trading days during the vesting period of the option. |